Fulcrum Therapeutics (FULC) Misleading Case
Fulcrum disclosed the FDA's full clinical hold on FTX-605.
Fulcrum's stock price fell 56%, seriously damaging investors.
Investors may suspect the Company, Its Leaders, or its Service Providers of misleading.
On February 24, 2023, Fulcrum disclosed that "the FDA verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease. The Agency indicated that it would provide a formal Clinical Hold Letter to the company within 30 days."
On February 24, 2023, Fulcrum's stock price fell 56%, seriously damaging investors.
Then, on March 9, 2023, Fulcrum announced recent business highlights and the Company’s Q4 and full-year 2022 financial results. The press release provided that in the clinical hold letter the Company received on February 24, 2023, the FDA referenced “preclinical data previously submitted in April, October, and December 2022, and non-clinical and clinical evidence of hematological malignancies observed with other inhibitors of polycomb repressive complex 2 (PRC2),” and noted that “the profile of hematological malignancies observed in the non-clinical studies of FTX-6058 is similar to that observed with other inhibitors of PRC2, and that hematological malignancies have been reported clinically with other PRC2 inhibitors.” Finally, the FDA requested that Fulcrum “further define the population where the potential benefit of continued treatment with FTX-6058 outweighs the potential risk.”
On this news, Fulcrum’s stock price fell 23%.
Taking all representations, Investors may have reasons to suspect the Company, Its Leaders, or its Service Providers of misleading statements and failure to timely disclose the truth about business prospects.